| Market Cap | 25.83M | P/E | - | EPS this Y | 16.00% | Ern Qtrly Grth | - |
| Income | -24.57M | Forward P/E | -1.18 | EPS next Y | 14.30% | 50D Avg Chg | -94.00% |
| Sales | - | PEG | -0.02 | EPS past 5Y | - | 200D Avg Chg | -95.00% |
| Dividend | N/A | Price/Book | 0.31 | EPS next 5Y | 60.00% | 52W High Chg | -98.00% |
| Recommedations | 2.00 | Quick Ratio | 21.74 | Shares Outstanding | 60.58M | 52W Low Chg | 12.00% |
| Insider Own | 2.85% | ROA | -17.45% | Shares Float | 59.17M | Beta | 0.91 |
| Inst Own | 19.50% | ROE | -26.31% | Shares Shorted/Prior | 477.88K/466.55K | Price | 0.43 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 79,645 | Target Price | 4.50 |
| Oper. Margin | - | Earnings Date | Nov 2 | Volume | 26,946,654 | Change | -16.75% |
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.